When people learn there's a pill that's been available for many years, that will keep them safe from HIV. They are surprised and may want to know more. And when people are surprised and even upset, we know we need to do more.
Because of naloxone’s ability to reverse opioid overdose and its ease of use, by July 15, 2017, all 50 states and the District of Columbia had passed legislation to improve naloxone access, as one strategy to reduce opioid overdose morbidity and mortality.
This webinar companion guide provides information for the January 2021 Strengthening Systems of Care: Supporting People with HIV and Opioid Use Disorder following Incarceration webinar.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.
This document contains slides for the September 2020 Models of Integrated Care for HIV and Opioid Use Disorder: Considerations for Community and Clinical Settings webinar.
Developed as part of the Strengthening Systems of Care for People with HIV and Opioid Use Disorder project, this document contains brief descriptions of federal policy and systems changes due to coronavirus 2019 (COVID-19) that relate to the HIV and substance use systems of care, along w
This article includes a case report example from Boston Medical Center focused on prescribing buprenorphine via telehealth, an approach made possible by regulatory changes during the COVID-19 pandemic.
